Phaseline

Companies › Vasgene Therapeutics

Vasgene Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Sep 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SEphB4-HSA
Ephrin-B2 inhibitor
EFNB2Phase 2Muscle-Invasive Bladder Carcinoma; Stage IV Bladder Urothelial Carcinoma; Head and Neck Squamous Cell CarcinomaSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02495896SEphB4-HSAPhase 1Head and Neck Squamous Cell CarcinomaOncologyDec 2026
NCT02717156SEphB4-HSAPhase 2Stage IV Bladder Urothelial CarcinomaOncologyDec 2027
NCT06493552SEphB4-HSAPhase 2Muscle-Invasive Bladder CarcinomaOncologySep 2029

Targets

EFNB2 (1)

Companies with the same targets

Mediar Therapeutics

Companies built like this

Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics Tessa Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.